Hamamatsu partners with Vizgen to deliver biomarker-detecting imaging technique
Immunofluorescence multiplex image of human FFPE IBD colon tissue (Left), with 21 biomarkers alongside virtual image (Right) (Image: Kennedy Institute of Rheumatology)
Hamamatsu’s multiplex immunofluorescence (mIF) imaging system, MoxiePlex, integrates with Vizgen’s pathology-grade reagent and assay portfolio to further clinical research applications
Register for FREE to keep reading
Join 10,000+ vision professionals driving innovation in automation, AI and imaging with:
- Expert insights on vision, robotics, AI & embedded tech
- Newsletters and features covering the full imaging landscape
- Visionaries series: leadership strategies in imaging
- Free panels on smart manufacturing & autonomy
- White Papers & updates for smarter integration
Sign up now
Already a member? Log in here
Your data is protected under our privacy policy.
